Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries

Mechanisms of resistance to immune checkpoint inhibitors

(2018) Russell W Jenkins et al.   BRITISH JOURNAL OF CANCER

Avelumab: a new standard for treating metastatic Merkel cell carcinoma

(2018) Mairead Baker et al.   Expert Review of Anticancer Therapy

A long non-coding SINEUP RNA boosts semi-stable production of fully human monoclonal antibodies in HEK293E cells

(2018) Emanuele Sasso et al.   mAbs

Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies

(2018) Emanuele Sasso et al.   mAbs

Identifying and managing the adverse effects of immune checkpoint blockade

(2018) Arthur Winer et al.   Journal of Thoracic Disease

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

(2018) Judith A. Seidel et al.   Frontiers in Oncology

Not All Immune Checkpoints Are Created Equal

(2018) Annika De Sousa Linhares et al.   Frontiers in Immunology

Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025

(2017) Bernard Escudier et al.   EUROPEAN UROLOGY

Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study

(2017) Joshua Bauml et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial

(2017) Georgina V Long et al.   LANCET ONCOLOGY

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

(2017) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma

(2016) H. Miyoshi et al.   BLOOD

Nivolumab in the Treatment of Hodgkin Lymphoma

(2016) Stephen M. Ansell   CLINICAL CANCER RESEARCH

Atezolizumab: A PD-L1–Blocking Antibody for Bladder Cancer

(2016) Brant A. Inman et al.   CLINICAL CANCER RESEARCH

What does PD-L1 positive or negative mean?

(2016) Antoni Ribas et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

(2016) F Stephen Hodi et al.   LANCET ONCOLOGY

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

(2016) Corey J Langer et al.   LANCET ONCOLOGY

Antibodies to watch in 2017

(2016) Janice M. Reichert   mAbs

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

(2015) Jeffrey S Weber et al.   LANCET ONCOLOGY

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment

(2015) G. K. Pennock et al.   ONCOLOGIST

Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS

(2015) Miguel F. Sanmamed et al.   SEMINARS IN ONCOLOGY

One-Step Recovery of scFv Clones from High-Throughput Sequencing-Based Screening of Phage Display Libraries Challenged to Cells Expressing Native Claudin-1

(2015) Emanuele Sasso et al.   Biomed Research International

Affinity Maturation of Monoclonal Antibody 1E11 by Targeted Randomization in CDR3 Regions Optimizes Therapeutic Antibody Targeting of HER2-Positive Gastric Cancer

(2015) Bong-Kook Ko et al.   PLoS One

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

(2013) Jedd D. Wolchok et al.   Annals of the New York Academy of Sciences

Therapeutic antibody engineering by high efficiency cell screening

(2013) Achim Doerner et al.   FEBS LETTERS

Overexpression and immunosuppressive functions of transforming growth factor 1, vascular endothelial growth factor and interleukin-10 in epithelial ovarian cancer

(2012) Chan-zhen Liu et al.   Chinese Journal of Cancer Research

Major histocompatibility complex class i and tumour immuno-evasion: how to fool T cells and natural killer cells at one time

(2012) D. Fruci et al.   Current Oncology

Affinity-based selection and the germinal center response

(2012) Tyani D. Chan et al.   IMMUNOLOGICAL REVIEWS

Protein selection using yeast surface display

(2012) Nimish Gera et al.   METHODS

Cells and cell lysates: A direct approach for engineering antibodies against membrane proteins using yeast surface display

(2012) Benjamin J. Tillotson et al.   METHODS

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

Engineering the variable region of therapeutic IgG antibodies

(2011) Tomoyuki Igawa et al.   mAbs

Antibody immunosuppressive therapy in solid-organ transplant

(2010) Nadim Mahmud et al.   mAbs

An improved yeast transformation method for the generation of very large human antibody libraries

(2010) Lorenzo Benatuil et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Critical evaluation of random mutagenesis by error-prone polymerase chain reaction protocols, Escherichia coli mutator strain, and hydroxylamine treatment

(2009) Tiina S. Rasila et al.   ANALYTICAL BIOCHEMISTRY

Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1

(2009) Dong-Ming Kuang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Mechanism and Regulation of Class Switch Recombination

(2008) Janet Stavnezer et al.   Annual Review of Immunology

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

A Decade of Yeast Surface Display Technology: Where Are We Now?

(2008) Eric Shusta et al.   COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING

Ig L-chain Shuffling for Affinity Maturation of Phage Library-derived Human Anti-human MCP-1 Antibody Blocking its Chemotactic Activity

(2008) K. Yoshinaga et al.   JOURNAL OF BIOCHEMISTRY

PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer

(2008) C A Crane et al.   ONCOGENE

Affinity maturation of antibodies assisted byin silicomodeling

(2008) Rodrigo Barderas et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

(2008) M. Marzec et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA